X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

X4 Pharmaceuticals reports positive trial results and financial resilience

X4 Pharmaceuticals showcased strong clinical performance with positive trial results for mavorixafor, while also strengthening its financial position despite reporting a net loss.
The company faces challenges in managing R&D expenses and addressing ongoing financial losses, but opportunities lie in market expansion and regulatory progress for mavorixafor.
By navigating challenges effectively and capitalizing on opportunities, X4 Pharmaceuticals can position itself for growth and success in advancing its lead candidate to market.
Investor interest, regulatory milestones, and strategic partnerships will play key roles in shaping X4 Pharmaceuticals' future trajectory and market competitiveness.

X4 Pharmaceuticals reports successful Phase III trial and plans FDA filing

X4 Pharmaceuticals demonstrated significant progress with mavorixafor and plans for regulatory filings, supported by a healthy cash position.
While facing challenges in managing expenses and achieving profitability, the company remains focused on advancing its pipeline and engaging with stakeholders.
Opportunities lie in upcoming events for collaboration and data dissemination, signaling potential growth avenues for X4 Pharmaceuticals.
Overall, X4 Pharmaceuticals' Q1 2023 earnings call highlighted achievements, financial standing, challenges, and future prospects for investors and stakeholders.

X4 Pharmaceuticals reports strong Q2 results and advances mavorixafor trials

X4 Pharmaceuticals showcased positive trial results and financial strength, positioning the company for future growth and market success.
While facing challenges in upcoming trials and commercialization, the company's strategic leadership and product potential offer opportunities for expansion.
Navigating regulatory processes and market dynamics will be key to realizing the full potential of mavorixafor and driving long-term value for stakeholders.
Overall, X4 Pharmaceuticals' focus on innovation, strategic partnerships, and market insights bode well for their competitive positioning and growth trajectory.

X4 Pharmaceuticals poised for mavorixafor launch in 2024

X4 Pharmaceuticals is on track for a significant mavorixafor launch in 2024, backed by strong financials and strategic initiatives. Challenges in patient diagnosis and access require focused efforts post-approval.

X4 Pharmaceuticals reports milestone achievements and financial stability for growth

X4 Pharmaceuticals showcased strong clinical advancements and financial stability in 2023, positioning them for potential FDA approval and market expansion.
While facing challenges in managing expenses and addressing stakeholder queries, the company remains optimistic about revenue opportunities and growth prospects.
With a focus on regulatory milestones, market entry strategies, and revenue generation, X4 Pharmaceuticals aims to capitalize on the momentum from their achievements.

X4 Pharmaceuticals reports FDA approval for XOLREMDI, faces financial challenges

X4 Pharmaceuticals faces financial challenges with a significant net loss despite having a substantial cash position.
The FDA approval of XOLREMDI for WHIM syndrome highlights the company's progress in drug development.
Opportunities lie in expanding XOLREMDI's market reach, monetizing PRV, and advancing R&D efforts for future growth.

X4 Pharmaceuticals excels in Phase II study and FDA approval, eyes market expansion in 2025

X4 Pharmaceuticals showcased positive results from the Phase II study of mavorixafor and FDA approval for XOLREMDI, signaling significant advancements in product development and market penetration.
While challenges exist in transitioning to Phase III trials and ensuring successful commercialization, the company's focus on physician comfort, disease awareness, and patient education presents opportunities for growth.
Overall, X4 Pharmaceuticals is well-positioned to capitalize on its recent achievements and drive further success through strategic initiatives in product development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. Its clinical candidate is mavorixafor. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Each brings significant experience in strategic marketing of rare disease therapeutics and commercial operations Each brings significant experience in strategic marketing of rare disease therapeutics and commercial operations

X4 Pharmaceuticals Expands Commercial Leadership Expertise with Appointment of Françoise de Craecker to Board of Directors and Karolyn Park as Vice President, U.S. Commercial

BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit and participate in a fireside chat at the Cantor Global Healthcare Conference.

X4 Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will conduct one-on-one investor meetings at the Citi 16th Annual BioPharma Conference and participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference.

X4 Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q2 2021 Results - Earnings Call Transcript

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at Canaccord Genuity's 41st Annual Growth Conference on Thursday, August 12, 2021.

X4 Pharmaceuticals to Participate at Canaccord Genuity's Virtual 41st Annual Growth Conference

XFOR is in phase 3 pivotal trials and its market cap is below $200mn.

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Twenty-three patients now enrolled in ongoing pivotal Phase 3 trial in WHIM syndrome, surpassing minimum needed for primary endpoint analyses; enrollment to complete in 3Q21 with top-line data expected in 4Q22

X4 Pharmaceuticals Announces Key Enrollment Milestone Achievements in Ongoing Mavorixafor Clinical Trials and Reports Second Quarter Financial Results

BOSTON, July 22, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the second quarter ended June 30, 2021, and provide an update on recent business highlights, on August 3, 2021.

X4 Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 3, 2021

Robust decreases in serum IgM at low- and mid-doses suggest best-in-class potential for mavorixafor plus ibrutinib therapy in double-mutation Waldenström's patients; meaningful increases in hemoglobin levels suggest reduction in cancer burden in bone marrow

X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström's Macroglobulinemia at EHA 2021

Poster presentation by lead author Dr. Steven Treon available on the EHA website  Friday, June 11, 2021 at 9:00 am CET/3:00 am ET

X4 Pharmaceuticals to Host Conference Call and Webcast to Present Initial Efficacy and Safety Data from EHA 2021 Poster on Phase 1b Clinical Trial of Mavorixafor in Waldenström's Macroglobulinemia

Initial data from first cohort of patients indicate mavorixafor plus ibrutinib to be well tolerated, with encouraging decreases in serum IgM observed

X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström's Macroglobulinemia as Published in EHA Abstract

X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q1 2021 Results - Earnings Call Transcript

Company continues to make significant clinical progress with lead candidate mavorixafor across multiple rare disease indications

X4 Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update

BOSTON, April 22, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the first quarter ended March 31, 2021, and provide an update on recent business highlights, on May 6, 2021.

X4 Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 6, 2021

BOSTON, April 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021.

X4 Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference

BOSTON, March 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it has agreed to sell an aggregate of 6,321,837 shares of its common stock, including pre-funded warrants to purchase common stock, to certain institutional accredited investors in a private investment in public equity (PIPE) financing. X4 anticipates that gross proceeds from the PIPE will be approximately $55.0 million, before deducting fees to the placement agents and other estimated offering expenses payable by the Company, based on the offering price of $8.70 per share (or $8.69 per pre-funded warrant), the last reported sale price of X4's common stock on The Nasdaq Global Market on March 18, 2021.

X4 Pharmaceuticals Announces $55.0 Million At-the-Market Private Placement Financing

X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q4 2020 Results - Earnings Call Transcript

2021 expected to be a year of key value-driving catalysts as company advances multiple  clinical programs with lead candidate mavorixafor

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at the B. Riley Oncology Institutional Investor Conference on Wednesday, January 20, 2021, at 11:00 am Eastern Time, and conduct one-on-one investor meetings around the event.

X4 Pharmaceuticals to Participate at the Virtual B. Riley Oncology Institutional Investor Conference

BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present at the H.C. Wainwright Virtual BioConnect Conference being held from January 11-14, 2021.   A webcast of the on-demand presentation will be available on the investor section of the X4 Pharmaceuticals website at www.x4pharma.com and at Presentation Webcast Link , beginning on Monday, January 11, 2021.

X4 Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect Conference

X4 Pharmaceuticals (XFOR) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

X4 Pharmaceuticals (XFOR) Surges: Stock Moves 6.9% Higher

BOSTON, Dec. 14, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the appointment of Diego Cadavid, M.D., as Chief Medical Officer. Dr. Cadavid will be responsible for the strategy, direction and execution of the company's clinical development programs.

X4 Pharmaceuticals Appoints Diego Cadavid, M.D., as Chief Medical Officer

BOSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it has received Rare Pediatric Disease (RPD) Designation from the U.S. Food and Drug Administration (FDA) for its lead asset, mavorixafor, for the treatment of WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. Mavorixafor is currently being investigated in a global pivotal Phase 3 clinical trial, 4WHIM, for the treatment of WHIM syndrome in patients who are 12 years of age and older.

X4 Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Mavorixafor for the Treatment of WHIM Syndrome

BOSTON, Nov. 10, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020, at 8:40 am Eastern Time, and conduct one-on-one investor meetings around the event.

X4 Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference

X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2020 Results - Earnings Call Transcript

News for X4 Pharmaceuticals Inc Stock (XFOR)